Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Amgen Will Cut Jobs

August 20, 2007 | A version of this story appeared in Volume 85, Issue 34

Amgen, the world's largest biotechnology company, will reduce staffing by 12-14% in response to lower sales of Aranesp, its erythropoiesis-stimulating agent (see page 34). The move will cost the company up to $700 million and result in the loss of 2,200 to 2,600 jobs. Despite the cuts, Amgen says it will continue to invest in R&D at "industry-leading levels."

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.